BidaskClub lowered shares of Forward Pharma A/S (NASDAQ:FWP) from a strong-buy rating to a buy rating in a research report report published on Thursday.

Separately, ValuEngine downgraded Forward Pharma A/S from a hold rating to a sell rating in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $24.00.

Shares of Forward Pharma A/S (NASDAQ FWP) traded up 3.64% during mid-day trading on Thursday, reaching $5.70. The company had a trading volume of 62,116 shares. Forward Pharma A/S has a 12 month low of $5.34 and a 12 month high of $33.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/22/forward-pharma-as-fwp-lowered-to-buy-at-bidaskclub.html.

The firm also recently declared an annual dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, September 7th were given a dividend of $22.903 per share. The ex-dividend date of this dividend was Wednesday, September 6th. Forward Pharma A/S’s dividend payout ratio (DPR) is presently -3,249.25%.

Several large investors have recently modified their holdings of FWP. MARSHALL WACE ASIA Ltd bought a new stake in shares of Forward Pharma A/S during the first quarter worth approximately $612,000. Marshall Wace North America L.P. bought a new stake in shares of Forward Pharma A/S during the first quarter worth approximately $612,000. Citadel Advisors LLC bought a new stake in shares of Forward Pharma A/S during the first quarter worth approximately $269,000. EcoR1 Capital LLC bought a new stake in shares of Forward Pharma A/S during the first quarter worth approximately $108,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Forward Pharma A/S during the first quarter worth approximately $2,465,000. Institutional investors own 21.85% of the company’s stock.

Forward Pharma A/S Company Profile

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.